oral semaglutide prescribing
Semaglutide Lurking Savings Over 4000 Weight Management
The FDA is removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, effectively ending large-scale compounding of these GLP-1 weight-loss drugs. The move follows a proposal announced in April 2024 and aims to curb unauthorized use while protecting the integrity of FDA-approved formulations. On April 30, 2024, the agency